Right to Try Amendments

Eligibility criteria changed from requiring a terminal illness to allowing patients with severe, debilitating, or life-threatening conditions who have limited treatment options.

Added investigational devices to the types of treatments patients can access under the Right to Try program.

Updated the definition of 'terminal illness' to explicitly include cancer diagnosed by a board-certified oncologist as a qualifying condition.

Added specific requirements for investigational devices and drugs to be currently undergoing FDA-compliant clinical investigations when treating eligible illnesses.

Added a new Section 58-85-107 requiring manufacturers to report patient numbers, illnesses treated, and adverse outcomes to the Health and Human Services Interim Committee within 30 days of providing an investigational product.

Reordered and renumbered definitions (e.g., 'Insurer' moved from definition 3 to 4) and updated the 'Medicinal dosage form' list to include 'formulation' as a specific term.

Modified the 'Terminal illness' definition by removing the requirement that the illness must inevitably lead to death if treated with an investigational drug, and removed the phrase 'and' before the alternative cancer diagnosis clause.

Removed the word 'and' from the end of several regulatory references (21 C.F.R. sections) and adjusted punctuation in the 'Investigational device' and 'Investigational drug' definitions.